12 May 2023 : Clinical Research
Outcomes of the Indonesian Chronic Disease Management Program (PROLANIS) in Patients with Hypertension During the COVID-19 Pandemic in Rural Areas: A Preliminary Evaluation Study
Sovia Salamah





DOI: 10.12659/MSM.939797
Med Sci Monit 2023; 29:e939797
Table 2 Six-month routine follow-up evaluation.
Evaluated parameters | N=91 | ||
---|---|---|---|
T0 | T1 | T2 | |
BMI in Kg/m, median [IQR] | 23.1 [20.6–25.3] | 23.4 [20.8–25.6] | 23.2 [21.3–25]=0.125 |
SBP in mmHg, median [IQR] | 130 [120–140] | 140 [120–145] | 140 [125–155] |
DBP in mmHg, median [IQR] | 80 [70–90] | 80 [80–90] | 80 [75–90]=0.106 |
TC in mg/dl, mean±SD | 207±42 | 217±41 | 206±42=0.724 |
LDL in mg/dl, mean±SD | 131±40 | 134±35=0.313 | 126±39=0.310 |
HDL in mg/dl, median [IQR] | 54 [48–63] | 58 [49–66]=0.897 | 45 [39–51] |
TG in mg/dl, median [IQR] | 145 [103–206] | 144 [100–209]=0.134 | 143 [99–197]=0.371 |
eGFR in ml/min/1.73 m, mean±SD | 80.8±18.8 | 75.9±21.5 | 75±21 |
BMI – body mass index; DBP – diastolic blood pressure; eGFR – estimated glomerular filtration rate based on CKD-EPI equation; HDL – high-density lipid; LDL – low-density lipid; TC – total cholesterol; TG – triglyceride; T0 – 6-month routine evaluation conducted in December 2019; T1 – 6-month routine evaluation conducted in June 2020; T2 – 6-month routine evaluation conducted in December 2020. Paired t-test was used for normally distributed data and Wilcoxon-signed rank test was used for skewed data. |